Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1985 Nov;62(2):380–386.

Immunofluorescent studies on alpha 2-plasmin inhibitor (alpha 2-PI) in glomeruli from patients with IgA nephropathy.

M Miura, Y Tomino, M Yagame, M Endoh, T Suga, Y Nomoto, H Sakai
PMCID: PMC1577439  PMID: 2935337

Abstract

Detection of alpha 2-plasmin inhibitor (alpha 2-PI) and/or fibrinogen in glomeruli by immunofluorescence in 26 patients with IgA nephropathy was described. The present study showed that glomerular injuries such as glomerular adhesion to Bowman's capsule and the cellular and/or fibrous crescent were predominantly observed in glomeruli with alpha 2-PI and/or fibrinogen deposits in patients with IgA nephropathy. Alpha 2-PI coexisted with fibrinogen in glomeruli from patients with IgA nephropathy. It was postulated that the deposition of alpha 2-PI in vivo might lead to the accumulation of glomerular fibrinogen deposits in patients with IgA nephropathy. It was suggested that the depositions of alpha 2-PI and/or fibrinogen in glomeruli may be one of the exacerbative factors in glomeruli from patients with IgA nephropathy.

Full text

PDF
380

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett N. B., Ogston D. Inhibitors of the fibrinolytic enzyme system in renal disease. Clin Sci. 1970 Nov;39(5):549–557. doi: 10.1042/cs0390549. [DOI] [PubMed] [Google Scholar]
  2. Berger J., Hinglais N. Les ddpôts intercapillaires d'IgA-IgG. J Urol Nephrol (Paris) 1968 Sep;74(9):694–695. [PubMed] [Google Scholar]
  3. Berger J., Yaneva H., Nabarra B., Barbanel C. Recurrence of mesangial deposition of IgA after renal transplantation. Kidney Int. 1975 Apr;7(4):232–241. doi: 10.1038/ki.1975.35. [DOI] [PubMed] [Google Scholar]
  4. Cameron J. S. The role of platelets in glomerulonephritis. Nihon Jinzo Gakkai Shi. 1983 Jul;25(7):786–797. [PubMed] [Google Scholar]
  5. Clarkson A. R., Woodroffe A. J., Bannister K. M., Lomax-Smith J. D., Aarons I. The syndrome of IgA nephropathy. Clin Nephrol. 1984 Jan;21(1):7–14. [PubMed] [Google Scholar]
  6. McCoy R. C., Abramowsky C. R., Tisher C. C. IgA nephropathy. Am J Pathol. 1974 Jul;76(1):123–144. [PMC free article] [PubMed] [Google Scholar]
  7. Moroi M., Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem. 1976 Oct 10;251(19):5956–5965. [PubMed] [Google Scholar]
  8. Sakata Y., Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest. 1982 Mar;69(3):536–542. doi: 10.1172/JCI110479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Shirai T., Tomino Y., Sato M., Yoshiki T., Itoh T. IgA nephropathy: clinicopathology and immunopathology. Contrib Nephrol. 1978;9:88–100. doi: 10.1159/000401436. [DOI] [PubMed] [Google Scholar]
  10. Tomino Y., Endoh M., Nomoto Y., Sakai H. Specificity of eluted antibody from renal tissues of patients with IgA nephropathy. Am J Kidney Dis. 1982 Mar;1(5):276–280. doi: 10.1016/s0272-6386(82)80025-5. [DOI] [PubMed] [Google Scholar]
  11. VASSALLI P., MCCLUSKEY R. T. THE PATHOGENIC ROLE OF FIBRIN DEPOSITION IN IMMUNOLOGICALLY INDUCED GLOMERULONEPHRITIS. Ann N Y Acad Sci. 1964 Aug 27;116:1052–1062. doi: 10.1111/j.1749-6632.1964.tb52567.x. [DOI] [PubMed] [Google Scholar]
  12. Wiman B., Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem. 1977 Aug 15;78(1):19–26. doi: 10.1111/j.1432-1033.1977.tb11709.x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES